Spinal Muscular Atrophy Market to Surge Owing to Gene Therapy Advances Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the degeneration of motor neurons, leading to progressive muscle wasting and severe disability. The Spinal Muscular Atrophy Market comprises innovative therapies such as antisense oligonucleotides, gene therapy, and small molecule treatments designed to modulate SMN protein levels. Products like nusinersen, onasemnogene abeparvovec, and risdiplam have demonstrated significant improvements in motor function, survival, and quality of life for patients across various disease types. Spinal Muscular Atrophy Market Opportunities in the SMA market stem from widening newborn screening initiatives, which facilitate early intervention and improve treatment efficacy. Orphan drug incentives and favorable reimbursement policies present attractive market opportunities for developers to launch premium-priced therapies. Expansion into emerging economies, enhanced patient registries, and digital health platforms offering remote monitoring can increase service reach. Global Spinal Muscular Atrophy Market size is estimated to be valued at USD 2,013.5 Mn in 2025 and is expected to exhibit a CAGR of 13.5% during the forecast period (2025-2032). Spinal Muscular Atrophy Market https://www.coherentmarketinsights.com/market-insight/spinal-muscular-atrophy-market-1920 Get More Insights On Spinal Muscular Atrophy Market https://justpaste.it/hzhyk #SpinalMuscularAtrophyMarket,#SpinalMuscularAtrophyMarketsize,#SpinalMuscularAtrophyMarketshare,#SpinalMuscularAtrophyMarketApplication,#SpinalMuscularAtrophyMarkettrends